,13–15 Recently, the CANTOS trial showed that targeted cytokine inhibition (IL-1β inhibition with Canakinumab) in CAD patients with a prior myocardial infarction and residual inflammatory risk reduced further cardiovascular events.16 Here, IL1B is linked to coronary artery disorder.